CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Jonathan Mazelsky

Executive Chair of the Board, Idexx Laboratories

Search every verified Jonathan Mazelsky interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. On IDEXX Laboratories' Q4 2024 earnings call, President and CEO Jonathan Mazelsky announced the March launch of the IDEXX Cancer DX panel with lymphoma detection, describing it as "a pioneering advancement in veterinary oncology." Mazelsky stated the panel has "breakthrough cost, performance, and turnaround time attributes" and will be priced "as little as $15 per test when included as part of select diagnostic panels." He said the panel will expand over three years to include the six most prevalent canine cancers, which he said "collectively account for over 50% of cancer cases in dogs" and represent "an estimated 1.1 billion addressable opportunity." Mazelsky noted that the company delivered "strong execution" in a "dynamic macro, economic and sector environment" with "continued pressure in clinical visits for pets visiting US clinics." He said pet owners "continued to demonstrate interest in a higher standard of care" and that "the inclusion of diagnostics actually went up" in wellness visits, with "really nice premium growth." Mazelsky attributed this to pet owners and veterinarians using "higher intensity of diagnostics," adding that "though there's probably some marginal pet owners dropping off... the ones that came in were very high quality."

Recent appearances

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →